The experimental weight-loss drug is a triple agonist and the first of its kind to reach a phase 3 clinical trial
Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs
Original Source
This article was collected from: Scientific American
Gabeshana News automatically collects article information
from external RSS/Atom sources. The original article remains
available at the source website. Please visit the original
source for the complete article and the latest information.